As summer heat turns to cool winds, hopes that this year would bring widespread industry relief have dissipated, with ...

The bacterium Clostridioides difficile is named “difficult” for a reason. Originally, it was hard to grow in the lab, and, ...

Against the backdrop of a Cas9 patent battle that refuses to die, Editas Medicine is cashing in a chunk of the licensing ...

A minority of patients taking Ultragenyx Pharmaceutical’s Wilson disease gene therapy UX701 have come off standard-of-care ...

Mosnodenvir is designed to block interactions between two dengue virus proteins. The vaccine survived J&J’s decision last ...

Prothena, a company focused on neurodegenerative diseases, is shaking up its C-suite. The exec moves were announced just a ...

Ten years after first collecting an FDA approval, it’s time for version number two. | Cologuard Plus represents the next ...

Legend Biotech appears to be on a mission to shake up its cell therapy development. | A week after signing up to collaborate ...

The digital pathology developer Proscia is launching an artificial intelligence toolkit for life science researchers, ...

Precision medicines biotech Relay Therapeutics is shedding about 10% of its workforce in efforts to streamline the ...

One of those companies, a contract research organization focused on genetic medicines called Franklin Biolabs, officially ...

Septerna is about to find out how a biotech without “any meaningful clinical data” fares in the late 2024 IPO market. | ...